Cognetivity Neurosciences Ltd
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $20.76 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Cognetivity Neurosciences Ltd had its IPO on under the ticker symbol CGNSF.
The company operates in the Healthcare sector and Health Information Services industry. Cognetivity Neurosciences Ltd has a staff strength of 0 employees.
Shares of Cognetivity Neurosciences Ltd opened at $0.24 at the start of the last trading session i.e. 2023-03-21.
The stocks traded within a range of $0.23 - $0.24, and closed at $0.23.
This is a -7.66% slip from the previous day's closing price.
A total volume of 4,000 shares were traded at the close of the day’s session.
In the last one week, shares of Cognetivity Neurosciences Ltd have slipped by -12.33%.
Cognetivity Neurosciences Ltd's Key Ratios
Cognetivity Neurosciences Ltd has a market cap of $20.76 million, indicating a price to book ratio of 189.0107 and a price to sales ratio of 0.
In the last 12-months Cognetivity Neurosciences Ltd’s revenue was $0 with a gross profit of $-4019164 and an EBITDA of $-10035756. The EBITDA ratio measures Cognetivity Neurosciences Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Cognetivity Neurosciences Ltd’s operating margin was 0% while its return on assets stood at -204.31% with a return of equity of -642.83%.
In Q3.3333333333333, Cognetivity Neurosciences Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Cognetivity Neurosciences Ltd’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.11 per share while it has a forward price to earnings multiple of 25.7732 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cognetivity Neurosciences Ltd’s profitability.
Cognetivity Neurosciences Ltd stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -1.1501. Its price to sales ratio in the trailing 12-months stood at 0.
Cognetivity Neurosciences Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $5.05 million
- Total Liabilities
- $4.71 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Cognetivity Neurosciences Ltd ended 2023 with $5.05 million in total assets and $0 in total liabilities. Its intangible assets were valued at $5.05 million while shareholder equity stood at $-6769932.00.
Cognetivity Neurosciences Ltd ended 2023 with $0 in deferred long-term liabilities, $4.71 million in other current liabilities, in common stock, $-28834413.00 in retained earnings and $0 in goodwill. Its cash balance stood at $4.12 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $1.24 million.
Cognetivity Neurosciences Ltd’s total current assets stands at $4.85 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $4.03 million and inventory worth $0.
In 2023, Cognetivity Neurosciences Ltd's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Cognetivity Neurosciences Ltd paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Cognetivity Neurosciences Ltd stock is currently trading at $0.23 per share. It touched a 52-week high of $0.322 and a 52-week low of $0.322. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.22 and 200-day moving average was $0.22 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 1469.3% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Cognetivity Neurosciences Ltd
Similar Industry Stocks (Health Information Services)
Cognetivity Neurosciences Ltd. operates as a technology company. It develops an integrated cognitive assessment, a cognitive testing platform for use in medical, commercial, and consumer environments that allows early diagnosis of dementia, as well as other neurological conditions. The company was formerly known as Utor Capital Corp. and changed its name to Cognetivity Neurosciences Ltd. in December 2017. Cognetivity Neurosciences Ltd. was incorporated in 2015 and is headquartered in Vancouver, Canada.